Does a bedtime H₂ blocker still have a role in the era of potassium-competitive acid blockers?

Introduction

Proton pump inhibitors (PPIs) have been the cornerstone of therapy for gastroesophageal reflux disease (GERD) for more than two decades. Yet, despite their proven efficacy, nocturnal acid breakthrough (NAB), defined as intragastric pH <4 lasting for at least 60 minutes at night, continues to be observed in 60% to 80% of patients receiving once-daily PPI therapy. The recent study, “Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole” (1), revisits this long-standing issue and suggests that supplementing PPI therapy with bedtime lafutidine not only suppresses NAB but also improves subjective sleep quality. This finding raises an important question for modern clinicians: does the bedtime H₂-blocker strategy still hold value in the era of potent potassium-competitive acid blockers (P-CABs)?

The paradox of NAB

Since its initial description, NAB has been considered a physiologic limitation of PPIs, whose activity wanes overnight due to short plasma half-life and meal-dependent activation. The addition of bedtime H₂-receptor antagonists (H₂RAs) was shown to reduce NAB in several studies during the early 2000s (2). However, the clinical meaning of NAB remains controversial (3). Not all episodes of gastric acidification translate into esophageal acid exposure or nocturnal reflux symptoms (4). Impedance-pH monitoring has revealed that many patients with NAB experience no corresponding reflux events or heartburn (5). Thus, the clinical relevance of NAB suppression must be interpreted beyond acid metrics alone.

Lafutidine’s unique pharmacology: beyond acid control

Lafutidine distinguishes itself from other H₂RAs by its dual mechanism. In addition to inhibiting histamine-mediated acid secretion, it activates capsaicin-sensitive sensory nerves, leading to calcitonin gene-related peptide (CGRP) release, improved mucosal blood flow, and enhanced epithelial defense (6,7). This neuroprotective pathway may underlie the observed improvement in sleep quality. Lafutidine could mitigate esophageal hypersensitivity or discomfort not solely by elevating intragastric pH, but also by modulating nociceptive signaling. In this sense, the bedtime lafutidine regimen might target the “sensory” component of nocturnal GERD symptoms—an often-overlooked mechanism in acid suppression trials.

P-CABs: redefining acid control

The introduction of P-CABs such as vonoprazan, tegoprazan, and fexuprazan has transformed acid suppression therapy. These agents achieve near-complete 24-hour intragastric pH control, including nocturnal periods, by reversibly and competitively blocking the H⁺/K⁺-ATPase independent of activation state (8). Several head-to-head trials and pharmacodynamic studies have shown that P-CABs provide more potent and sustained acid suppression than PPIs, with higher healing rates, particularly in severe erosive esophagitis and a lower frequency of NAB (8). In addition, owing to their rapid and consistent onset of action, P-CABs can achieve earlier improvement in GERD symptoms compared with conventional PPIs (9). In this context, a practical question emerges: is adding a bedtime H₂RA still necessary when a single daily P-CAB can maintain pH >4 throughout the night?

From a pharmacological perspective, H₂RA add-on therapy may provide short-term relief, especially in patients with transient nocturnal symptoms or during PPI titration. However, tachyphylaxis develops rapidly—often within one to two weeks—limiting long-term benefit (10). Conversely, switching to a P-CAB may offer sustained efficacy without the need for combination therapy.

Sleep quality: a patient-centered endpoint

A notable strength of this lafutidine study is the inclusion of sleep quality as an outcome measure, using the Pittsburgh Sleep Quality Index (PSQI). Sleep disturbance is highly prevalent in GERD and contributes to reduced daytime function and quality of life (11). Even modest improvement in sleep perception can translate into tangible clinical benefit. However, the reliance on subjective measures warrants cautious interpretation. Future studies incorporating objective sleep metrics—such as actigraphy or polysomnography—will be essential to validate whether perceived improvement corresponds to physiologic restoration.

Precision acid suppression: individualizing therapy

The value of adding a bedtime H₂RA likely depends on the patient’s symptom phenotype (12). Those most likely to benefit are patients with nocturnal or recumbent heartburn, patients with obstructive sleep apnea or a high body mass index (BMI), patients with large hiatal hernias, and those in whom pH-impedance monitoring has documented pathological night-time acid exposure. By contrast, patients with reflux hypersensitivity or functional heartburn are unlikely to respond to further intensification of acid suppression; in such cases, neuromodulators, behavioral therapy, or sleep-focused interventions may be more appropriate. This phenotypic strategy—aligning the therapeutic mechanism with the dominant symptom profile—illustrates the emerging paradigm of precision management in GERD.

Regional and practical considerations

In Japan and other parts of Asia, lafutidine remains widely available and cost-effective. For clinicians managing PPI-refractory GERD with nocturnal symptoms, lafutidine add-on therapy offers a pragmatic option, especially where P-CAB access or reimbursement is limited. Nevertheless, clinicians must consider polypharmacy, drug interactions, and the transient nature of H₂RA response. Short-term or intermittent use, guided by symptom recurrence, may balance efficacy with practicality.

Future directions

Future research should focus on longitudinal assessment of lafutidine’s efficacy and tachyphylaxis beyond four weeks, direct comparisons between lafutidine add-on and P-CAB switch strategies, and the integration of objective sleep analysis with detailed symptom-reflux correlation metrics. In parallel, further exploration of lafutidine’s sensory-neural modulation as a potential therapeutic mechanism is warranted. Collectively, such studies will help determine whether the bedtime H₂RA strategy remains broadly clinically relevant or instead evolves into a niche, phenotype-driven adjunct.

Conclusions

The addition of bedtime lafutidine to esomeprazole therapy reopens discussion on nocturnal acid suppression in GERD. While P-CABs have redefined the pharmacologic landscape, lafutidine’s dual mechanism, combining acid inhibition with sensory modulation, offers a nuanced therapeutic rationale, particularly for patients troubled by night-time symptoms and poor sleep. Ultimately, the key message is that effective GERD management is not merely about pH normalization but about improving patients’ nights, days, and lives.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Esophagus. The article did not undergo external peer review.

Funding: None.

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://aoe.amegroups.com/article/view/10.21037/aoe-2025-1-33/coif). The author has no conflicts of interest to declare.

Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy of integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Wang D, He R, Zhang X, et al. Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole: a randomized controlled trial. Sci Rep 2025;15:23286. [Crossref] [PubMed]
2. Wang Y, Pan T, Wang Q, et al. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev 2009;2009:CD004275. [Crossref] [PubMed]
3. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1392-1413, 1413.e1-5.
4. Ours TM, Fackler WK, Richter JE, et al. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003;98:545-50. [Crossref] [PubMed]
5. Karyampudi A, Ghoshal UC, Singh R, et al. Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease. J Neurogastroenterol Motil 2017;23:208-17. [Crossref] [PubMed]
6. Shimatani T, Inoue M, Kuroiwa T, et al. Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine. Dig Dis Sci 2006;51:114-20. [Crossref] [PubMed]
7. Akiba Y, Kaunitz JD. Lafutidine, a protective H2 receptor antagonist, enhances mucosal defense in rat esophagus. Dig Dis Sci 2010;55:3063-9. [Crossref] [PubMed]
8. Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil 2018;24:334-44. [Crossref] [PubMed]
9. Oshima T, Arai E, Taki M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther 2019;49:140-6. [Crossref] [PubMed]
10. Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625-32. [Crossref] [PubMed]
11. Mody R, Bolge SC, Kannan H, et al. Effects of gastroesophageal reflux disease on sleep and outcomes. Clin Gastroenterol Hepatol 2009;7:953-9. [Crossref] [PubMed]
12. Mermelstein J, Chait Mermelstein A, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol 2018;11:119-34. [Crossref] [PubMed]